Clinical trial
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
NCT00027599 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00027599 |
|---|---|
| Title | APC8015 and Bevacizumab in Treating Patients With Prostate Cancer |
| Official title | A Phase II Study Of Prostatic Acid Phosphatase-Pulsed Dendritic Cells (Provenge) In Combination With Bevacizumab In Patients With Serologic Progression Of Prostate Cancer After Definitive Local Therapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Procedure |
| Interventions | bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation |
| Enrollment | 25 |
| Start date | Dec 1, 2001 |
| Primary completion | Jul 1, 2007 |
| First posted | May 7, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: